MEDVi Review 2026: Compounded Tirzepatide & Semaglutide Program Breakdown

What Is MEDVi?

MEDVi is a telehealth platform specifically designed around GLP-1 medications, offering access to both compounded semaglutide and compounded tirzepatide — the two leading peptides in the medical weight loss space. What sets MEDVi apart from many competitors is their dual-peptide capability and their reputation within the affiliate and clinical communities for producing strong patient outcomes and smooth patient journeys.

In the telehealth GLP-1 industry, MEDVi is known — to borrow the clinical community's language — for "high conversions and a seamless patient experience." That reputation is earned through operational quality, not marketing spend.

MEDVi Pricing

MEDVi's pricing reflects their dual-peptide capability and operational quality:

• Compounded semaglutide: Approximately $229–$299/month
• Compounded tirzepatide: Approximately $299–$399/month
• Initial consultation: Typically included in first-month cost
• Follow-up support: Included in monthly subscription

MEDVi sits in the mid-range for the market — not the cheapest option, but the pricing reflects clinical quality that cheaper programs often compromise on.

Semaglutide vs. Tirzepatide: Which Does MEDVi Do Better?

MEDVi's tirzepatide program is particularly notable because tirzepatide (the active ingredient in Zepbound and Mounjaro) targets both GLP-1 and GIP receptors — producing stronger average weight loss in clinical trials than semaglutide alone. At the time of this review, tirzepatide compounding remains available because the tirzepatide shortage has not been formally ended by the FDA, unlike semaglutide.

For patients who want to maximize weight loss outcomes and can tolerate the GIP mechanism's different side effect profile, MEDVi's tirzepatide program is a compelling offering. For patients who want semaglutide specifically, their semaglutide program is equally solid.

The Onboarding Experience

MEDVi has invested heavily in the patient onboarding experience, and it shows:

1. Clean, intuitive intake flow — one of the better-designed onboarding experiences in the category
2. Fast provider review — typically 24 hours or less for standard cases
3. Clear prescription status updates — patients are kept informed at each stage
4. Pharmacy coordination handled internally — patients don't navigate pharmacy logistics themselves

This seamless experience is the "patient journey" quality that MEDVi is recognized for in the industry.

Pharmacy and Clinical Quality

MEDVi sources through accredited compounding partners and applies legitimate clinical eligibility standards. Patients are evaluated for appropriate candidacy — this isn't a prescription mill. The clinical oversight layer includes genuine prescriber review, not just automated approvals based on BMI alone.

Who Is MEDVi Best For?

• Patients who want the option of tirzepatide (currently more accessible than compounded semaglutide post-shortage)
• Anyone who values a premium patient experience and clear communication throughout their program
• Patients comparing multiple peptides and wanting a single platform to try both
• Those who've had frustrating experiences with disorganized telehealth programs and want something more polished

Our Verdict on MEDVi

MEDVi earns its strong reputation. The combination of dual-peptide capability, polished patient experience, and clinical quality makes it one of the top programs in the compounded GLP-1 market. It's not the cheapest option, but patients who prioritize experience quality over price minimization will find MEDVi consistently delivers.